Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis Pharmaceutical TechnologyBMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).Immunology & InflammationRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) Pharmaceutical Technology BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA). Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pulsesight reports positive phase 1 data for PST611 in dry AMDNext: Deal finally unlocks NHS access to ITF’s Duchenne drug Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
